Table 1. Baseline characteristics of the study group.

ALBI: albumin-bilirubin; SEC: seven-eleven criteria; AFP: alpha-fetoprotein; HCC: hepatocellular carcinoma; TBS: tumour burden score

Total number of patients (47)	F4 (43 patients—91.49%)				F3 (4 patients—8.51%)
	Decompensated cirrhosis (26 patients—55.32%)		Compensated cirrhosis (17 patients—36.17%)
	Solitary HCC nodule N=6 patients (23%)	Multinodular HCC N=20 patients (77%)	Solitary HCC nodule N=2 patients (11.76%)	Multinodular HCC N=15 patients (88.23%)	Solitary HCC nodule N=3 patients (75%)	Multinodular HCC N=1 patient (25%)
Mean age	48.23+/- 15.02	53.83 +/- 17.45	51.21 +/- 21.83	51.87 +/- 16.75	48.33 +/- 18.13	53.78 +/- 21.05
Gender—female (27 patients—57.44%)	3 patients (50%)	12 patients (60%)	1 patient (50%)	9 patients (60%)	1 patient (33.33%)	1 patient (100%)
AFP=100-300 ng/ml (18 patients—38.29%)	1 patient (3.84%)		13 patients (76.47%)		4 patients (100%)
AFP=300-500 ng/ml (17 patients—36.17 %)	15 patients (57.69%)		2 patients (11.76%)		0
AFP > 500 ng/ml (12 patients—25.53%)	10 patients (38.46%)		2 patients (11.76%)		0
Mean AFP (ng/ml)	660		278		250
Mean HCC size (cm)	5.8		3.5		3
Low TBS (13 patients—27.65%)	0		9 patients (52.94%)		4 patients (100%)
Medium TBS (34 patients—72.34%)	26 patients (100%)		8 patients (47.06%)		0
High TBS	0		0		0
Low SEC (31 patients—65.96%)	12 patients (46.15%)		15 patients (88.24%)		4 patients (100%)
Medium SEC (16 patients—34.04%)	14 patients (53.84%)		2 patients (11.76%)		0
High SEC	0		0		0
ALBI grade 1 (4 patients—8.51%)	0		0		4 patients (100%)
ALBI grade 2 (30 patients—63.82%)	13 patients (50%)		17 patients (100%)		0
ALBI grade 3 (13 patients—27.65%)	13 patients (50%)		0		0